Trials / Completed
CompletedNCT02202473
Oxymatrine Plus Lamivudine Combination Therapy Versus Lamivudine Monotherapy for Chronic Hepatitis B Infected Subjects
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 192 (actual)
- Sponsor
- Southeast University, China · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of Oxymatrine plus Lamivudine Combination Therapy and whether it could lower the incidence of Lamivudine long-term resistance compared to Lamivudine Monotherapy.
Detailed description
Group A (Lamivudine Monotherapy): Lamivudine (Manufacturer: GlaxoSmithKline) 100mg po, qd. Group B (Oxymatrine + Lamivudine Combination Therapy): Lamivudine (Manufacturer: GlaxoSmithKline) 100mg po, qd; oxymatrine Capsules (Chia Tai Tianqing Pharmaceutical Group Co., Ltd) 200 mg, po, tid. Total subjects: 200, 100 patients randomized in each group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lamivudine | |
| DRUG | Lamivudine+Oxymatrine Capsules |
Timeline
- Primary completion
- 2014-02-01
- First posted
- 2014-07-29
- Last updated
- 2014-07-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02202473. Inclusion in this directory is not an endorsement.